Clinical Trial

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

Name: A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease — clinical trial record (NCT04929210)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: STAR

Active, Not Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

Trial Details

NCT Number	NCT04929210
Lead Sponsor	Janssen Research & Development, LLC
Conditions	Arthritis, Psoriatic
Enrollment	411 participants
Start Date	2021-08-30
Primary Completion	2026-08-04 (estimated)
Study Completion	2027-04-13 (estimated)
Updated on ClinicalTrials.gov	2026-07-06